None of the 29 investors followed here reported a position in SPTX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SPTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 21, 2026 | Hombach Robert J. CpaDirector | Purchase at price 18.14 per share. | 13K | $235.77K |
| May 3, 2026 | Paul Steven MDirector | — | 67K | — |
| May 3, 2026 | Healy James IDirector | — | 2.73M | — |
| May 3, 2026 | Torres DeniceDirector | — | 13.4K | — |
| May 3, 2026 | White LaurenChief Financial Officer | — | 6.7K | — |
| May 3, 2026 | Puretech Health PlcBeneficial Owner of more than 10% of a Class of Security | — | 16.38M | — |
| May 3, 2026 | Arch Venture Partners Xii, LlcBeneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 1.10M | $19.80M |
| May 3, 2026 | Arch Venture Partners Xii, LlcBeneficial Owner of more than 10% of a Class of Security | — | 5.19M | — |
| May 3, 2026 | Loebel Antony M.D.Officer | — | 20.1K | — |
| May 3, 2026 | Chen Michael Cunyuan Ph.D.Officer | — | 3.4K | — |
| May 3, 2026 | Gladstein Lana J.D.General Counsel | — | 33.5K | — |
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.
Buy / hold / sell counts